Altimmune jumps as experimental obesity drug shows benefit in alcohol use disorder study

Altimmune

28/07/2026 12:33

** Shares of drug developer Altimmune ALT.O rise ~19% to $3.51 premarket   
** Co says its experimental weight-loss drug, pemvidutide, met the main goal of a mid-stage study in patients with moderate to severe alcohol use disorder
** The drug helped significantly reduce heavy drinking days compared with placebo, the main goal of the study - ALT 
** Nearly two-thirds of patients treated with pemvidutide also achieved a two-level reduction in their WHO-RDL, a secondary goal of the study - ALT 
** WHO-RDL categorizes average daily or weekly alcohol consumption into no risk, low risk, medium risk, high risk, and very high risk    
** Pemvidutide belongs to the same class of drugs as Novo Nordisk's NOVOb.CO  Wegovy , and Eli Lilly's LLY.N  Zepbound, known as GLP-1 agonists
** It is also being tested to treat metabolic dysfunction-associated steatohepatitis, or MASH, a serious type of fatty liver disease
** Up to last close, ALT stock has fallen 18% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))